MiNK Therapeutics, Inc.

NASDAQ: INKT · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001840229Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 28DQ —GM —SS 36

v0.1 · 35/100 weight · pillars only

↑ market scale, return on assets · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$12.5M

Employees

as of 2026-08-19

Market cap

$59.8M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$12.5M-$12.5M2025

Operating income-$12.6M-$12.6M2025

Total assets$14.2M$14.2M2025

Equity-$14.2M-$14.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is MiNK Therapeutics, Inc.’s financial profile?

MiNK Therapeutics, Inc. earned -$12.5M in FY2025 net income.

Peers · Healthcare

Citius Oncology, Inc.——Boundless Bio, Inc.——MindWalk Holdings Corp.——BioStem Technologies, Inc.——Apollomics, Inc.——Mach7 Technologies Limited——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOJennifer S. Buell

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: INKT

Employees15

IPO date2021-10-15

Latest filings

10-Q2026-08-13 8-K2026-08-13 8-K2026-06-23 8-K2026-05-15 10-Q2026-05-15 DEF 14A2026-04-30 8-K2026-03-31 10-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.